Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi benefitted from an additional 12 weeks of treatment, according to study results in ...
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback